Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-selective guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure−activity relationship (SAR) studies of three scaffold components: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these limitations, we have explored bioisosteres of the biaryl moiety and modifications of the guanidine core. These investigations have yielded the aryl-alkyl ether derivative IGUANA-5, a potent ALDH1B1 inhibitor that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits enhanced in vitro and in vivo pharmacological properties. Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.